Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2029-01-28
Target enrollment:
Participant gender:
Summary
This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer
trait (biomarker) will determine to which sub-study, within this protocol, a participant will
be assigned to compare new targeted cancer therapy, designed to block the growth and spread
of cancer, or combinations to standard of care therapy with the ultimate goal of being able
to approve new targeted therapies in this setting. In addition, the protocol includes
non-match sub-studies which will include all screened patients not eligible for any of the
biomarker-driven sub-studies.